Mitsubishi UFJ Trust & Banking Corp Takes $1.44 Million Position in Elanco Animal Health Incorporated $ELAN

Mitsubishi UFJ Trust & Banking Corp acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 71,674 shares of the company’s stock, valued at approximately $1,444,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. SJS Investment Consulting Inc. raised its position in shares of Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after purchasing an additional 1,333 shares during the period. Farther Finance Advisors LLC increased its stake in Elanco Animal Health by 79.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in Elanco Animal Health by 184.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after buying an additional 2,414 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in Elanco Animal Health by 261.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock valued at $58,000 after buying an additional 2,922 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after buying an additional 2,080 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. Barclays assumed coverage on Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price target on the stock. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. Finally, Morgan Stanley lifted their target price on Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.44.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $24.05 on Friday. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $25.29. The company has a market cap of $11.95 billion, a P/E ratio of 400.90, a P/E/G ratio of 3.38 and a beta of 1.87. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The stock’s 50-day simple moving average is $23.02 and its 200 day simple moving average is $20.31.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.13 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Activity

In other news, CEO Jeffrey N. Simmons purchased 22,000 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were purchased at an average cost of $21.75 per share, with a total value of $478,500.00. Following the completion of the transaction, the chief executive officer owned 167,000 shares of the company’s stock, valued at $3,632,250. The trade was a 15.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert M. Vanhimbergen purchased 6,950 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $21.64 per share, with a total value of $150,398.00. Following the purchase, the chief financial officer owned 124,233 shares of the company’s stock, valued at approximately $2,688,402.12. The trade was a 5.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 43,450 shares of company stock valued at $937,883 in the last ninety days. Corporate insiders own 0.89% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.